Mark Velleca, StrideBio CEO
April 5, 2023 10:53 AM EDTUpdated 02:04 PM
Deals
R&D

Gink­go snaps up gene ther­a­py vec­tor as­sets from Stride­Bio

Tyler Patchen

News Reporter

Gink­go Bioworks is pick­ing up some vi­ral vec­tors, part of what it calls an on­go­ing push in­to gene ther­a­py ser­vices.

On Wednes­day, Gink­go an­nounced that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times